Department of Clinical Laboratory, Tianjin Central Hospital of Obstetrics and Gynecology, No. 156, Nankai Three Road, Tianjin, China.
Arch Gynecol Obstet. 2020 Mar;301(3):779-785. doi: 10.1007/s00404-020-05447-z. Epub 2020 Feb 8.
In this study, the prognostic value of serum HE4 was investigated in patients with advanced ovarian, fallopian tube, and peritoneal carcinoma.
Serum HE4 and CA125 levels were measured in both patients and controls, and the response of treatment and the detection of recurrence were evaluated by serum HE4 and CA125 levels in the patients.
The results showed that the levels of serum HE4 and CA125 were significantly higher in advanced patients than those seen in benign disease controls (p < 0.001). Compared with CA125, HE4 had higher specificity, but lower sensitivity. Furthermore, serum HE4 was closely associated with the response of treatment and recurrence, the effective response rate for therapy treatment showed by HE4 was higher than CA125, and a serum HE4 level was correlated with a sensitivity of 82.8% and a specificity of 99%, a positive predictive value (PPV) of 97.7%, and a negative predictive value (NPV) of 77.9% to show the presence of recurrence; the accuracy of HE4 for recurrence prediction after treatment was 88.6%.
Our study indicated that serum HE4 levels are effective for diagnosis, evaluating the response of treatment and predicting recurrence in patients with advanced ovarian, fallopian tube, and peritoneal carcinoma.
本研究旨在探讨血清 HE4 在晚期卵巢、输卵管和腹膜癌患者中的预后价值。
测量患者和对照组的血清 HE4 和 CA125 水平，并通过患者的血清 HE4 和 CA125 水平评估治疗反应和检测复发。
结果表明，晚期患者的血清 HE4 和 CA125 水平明显高于良性疾病对照组（p<0.001）。与 CA125 相比，HE4 具有更高的特异性，但敏感性较低。此外，血清 HE4 与治疗反应和复发密切相关，HE4 显示的治疗有效反应率高于 CA125，血清 HE4 水平与灵敏度 82.8%、特异性 99%、阳性预测值（PPV）97.7%和阴性预测值（NPV）77.9%相关，以显示复发的存在；治疗后 HE4 对复发的预测准确率为 88.6%。
本研究表明，血清 HE4 水平可有效用于诊断、评估治疗反应和预测晚期卵巢、输卵管和腹膜癌患者的复发。
